Flex Pharma (FLKS) Tops Q3 EPS by 7c

Flex Pharma (NASDAQ: FLKS) reported Q3 EPS of ($0.54), $0.07 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $414 thousand versus the consensus estimate of $480 thousand.

Based on its current operating plans and cash, cash equivalents and marketable securities position, Flex Pharma expects to have sufficient capital to fund its operations into early 2019.

For earnings history and earnings-related data on Flex Pharma (FLKS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance